Markets

Cash supplement: China Gewang Biotechnology files for a $12 million Nasdaq IPO

China Gewang Biotechnology, which sells nutritional supplements in China, filed on Monday with the SEC to raise up to $12 million in an initial public offering on a major exchange. The company is currently listed on the OCTQB under the symbol CGWB.

The Guangzhou City, China-based company was founded in 2010 and booked $21 million in sales for the 12 months ended August 31, 2016. It plans to list on the Nasdaq under the symbol CGWB. ViewTrade is the sole bookrunner on the deal. No pricing terms were disclosed.

The article Cash supplement: China Gewang Biotechnology files for a $12 million Nasdaq IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

IPOs